Western blot analysis of CD47 was performed by loading 25 ug of human placenta (lane 1), Jurkat (lane 2) and BAF-3 (lane 3) cell lysates onto an SDS polyacrylamide gel. Proteins were transferred to a PVDF membrane and blocked at 4°C overnight. The membrane was probed with a CD47 monoclonal antibody (Product # MA5-11895) at a dilution of 1:50 overnight at 4°C, washed in TBST, and probed with an HRP-conjugated secondary antibody for 1 hr at room temperature in the dark. Chemiluminescent detection was performed using Pierce ECL Plus Western Blotting Substrate (Product # 32132). Results show a band at ~42 and 52kDa.
|Tested species reactivity||Human|
|Published species reactivity||Human|
|Host / Isotype||Mouse / IgG1, kappa|
|Immunogen||Intact CD47 purified from placenta|
|Storage buffer||PBS, pH 7.4, with 0.2% BSA|
|Contains||0.09% sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||0.5 ug/test|
|Immunofluorescence (IF)||Assay Dependent|
|Immunoprecipitation (IP)||2 µg/ml|
|Western Blot (WB)||1:10-1:100|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Blocking Assay (BLOCK)||See 5 publications below|
MA5-11895 targets CD47 in WB, FACS, IF, and IP applications and shows reactivity with Human samples.
The MA5-11895 immunogen is intact CD47 purified from placenta.
CD47 antigen, also known as integrin associated-protein (IAP), is expressed on all hematopoietic cells, including leukocytes, platelets and erythrocytes. It is also expressed on epithelial cells, endothelial cells, fibroblasts and many tumor cell lines. CD47 may play a role as a signal transducer in the regulation of cation fluxes across cell membranes and in the chemotactic and adhesive interactions of leukocytes with endothelial cells.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
A cytokine-controlled mechanism for integrated regulation of T-lymphocyte motility, adhesion and activation.
MA5-11895 was used in blocking or activating experiment and western blot to study the mechanism underlying cytokine-mediated modulation of the motility, adhesion and activation of T-cells
|Bergström SE,Bergdahl E,Sundqvist KG||Immunology (140:441)||2013|
Latency associated peptide has in vitro and in vivo immune effects independent of TGF-beta1.
MA5-11895 was used in blocking or activating experiment to study the TGF-beta1-independent immune effects of latency associated peptide
|Ali NA,Gaughan AA,Orosz CG,Baran CP,McMaken S,Wang Y,Eubank TD,Hunter M,Lichtenberger FJ,Flavahan NA,Lawler J,Marsh CB||PloS one (3:null)||2008|
Erythrocyte adhesion is modified by alterations in cellular tonicity and volume.
MA5-11895 was used in blocking or activating experiment to study the effect of cellular tonicity and volume on erythrocyte adhesion
|Wandersee NJ,Punzalan RC,Rettig MP,Kennedy MD,Pajewski NM,Sabina RL,Paul Scott J,Low PS,Hillery CA||British journal of haematology (131:366)||2005|
The C-terminal 26-residue peptide of serpin A1 stimulates proliferation of breast and liver cancer cells: role of protein kinase C and CD47.
MA5-11895 was used in blocking or activating experiment to study the mechanism by which the C-terminal peptide of serpin A1 stimulates proliferation of breast and liver cancer cells
|Congote LF,Temmel N||FEBS letters (576:343)||2004|
Increased erythrocyte adhesion in mice and humans with hereditary spherocytosis and hereditary elliptocytosis.
MA5-11895 was used in blocking or activating experiment to study multiorgan thrombosis and infarction in mice and humans with hereditary spherocytosis and hereditary elliptocytosis
|Wandersee NJ,Olson SC,Holzhauer SL,Hoffmann RG,Barker JE,Hillery CA||Blood (103:710)||2004|